Kim Stratton

Chief Executive Officer at CENTOGENE, Rostock

Kim Stratton serves as Chief Executive Officer at CENTOGENE, the essential life science partner for data-driven answers in rare and neurodegenerative diseases. Kim has more than 30 years’ global commercial expertise in the biopharmaceutical space, with significant experience across multiple geographies, including Europe, the U.S., APAC, and LATAM. Most recently, Kim served as CEO of Orphazyme, a biopharmaceutical company dedicated to developing treatments for patients living with rare diseases. Prior to this role, she worked at Shire Pharmaceuticals, where she served as Head of International Commercial for Shire’s Specialty and Rare Disease portfolio. Before Shire, Kim spent nearly 15 years at Novartis in a number of senior management roles, including Global Head Corporate Public Affairs, Global Business Franchise Head, and Country Management. Kim is on the Board of Recordati S.p.A and Novozymes A/S.

2:00 - 2:40 PM

Day 1 Conference

Panel 3 - Startups

Venue: City Council Hall


In this panel the focus will be on launching and developing startups. We will discuss general conditions and challenges, differences in their development in Germany and USA and opportunities for expansion. We will talk about Rostock as a business location, Life Sciences and investment possibilities.